December 1st 2005
In the past decade there has been arapid increase in our understandingof the biology of multiple myelomaand the development of newtreatment strategies. In the currentissue of ONCOLOGY, Richardson etal provide an excellent overview ofnew agents in the treatment of multiplemyeloma. Two of these agentsare currently available in the UnitedStates outside of clinical trials: thalidomide(Thalomid) and bortezomib(Velcade). The thalidomide analog-lenalidomide (Revlimid)-will likelybe available in the near future,while several other novel agents arebeing evaluated in clinical trials.Richardson and colleagues haveplayed a major role in the developmentof bortezomib and lenalidomide,as well as numerous novel agentscurrently in clinical trials. Their reviewis therefore particularly enlightening,and provides a first-handaccount of the clinical developmentof various new drugs for the treatmentof myeloma.